Anders Ettrup1, Claus Svarer1, Brenda McMahon2, Sofi da Cunha-Bang2, Szabolcs Lehel3, Kirsten Møller4, Agnete Dyssegaard1, Melanie Ganz1, Vincent Beliveau2, Louise Møller Jørgensen2, Nic Gillings3, Gitte Moos Knudsen5. 1. Neurobiology Research Unit, Center for Integrated Molecular Brain Imaging (Cimbi), Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. 2. Neurobiology Research Unit, Center for Integrated Molecular Brain Imaging (Cimbi), Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. 3. Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. 4. Department of Neuroanaesthesiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. 5. Neurobiology Research Unit, Center for Integrated Molecular Brain Imaging (Cimbi), Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: gmk@nru.dk.
Abstract
INTRODUCTION: [(11)C]Cimbi-36 is a recently developed serotonin 2A (5-HT2A) receptor agonist positron emission tomography (PET) radioligand that has been successfully applied for human neuroimaging. Here, we investigate the test-retest variability of cerebral [(11)C]Cimbi-36 PET and compare [(11)C]Cimbi-36 and the 5-HT2A receptor antagonist [(18)F]altanserin. METHODS: Sixteen healthy volunteers (mean age 23.9 ± 6.4years, 6 males) were scanned twice with a high resolution research tomography PET scanner. All subjects were scanned after a bolus of [(11)C]Cimbi-36; eight were scanned twice to determine test-retest variability in [(11)C]Cimbi-36 binding measures, and another eight were scanned after a bolus plus constant infusion with [(18)F]altanserin. Regional differences in the brain distribution of [(11)C]Cimbi-36 and [(18)F]altanserin were assessed with a correlation of regional binding measures and with voxel-based analysis. RESULTS: Test-retest variability of [(11)C]Cimbi-36 non-displaceable binding potential (BPND) was consistently <5% in high-binding regions and lower for reference tissue models as compared to a 2-tissue compartment model. We found a highly significant correlation between regional BPNDs measured with [(11)C]Cimbi-36 and [(18)F]altanserin (mean Pearson's r: 0.95 ± 0.04) suggesting similar cortical binding of the radioligands. Relatively higher binding with [(11)C]Cimbi-36 as compared to [(18)F]altanserin was found in the choroid plexus and hippocampus in the human brain. CONCLUSIONS: Excellent test-retest reproducibility highlights the potential of [(11)C]Cimbi-36 for PET imaging of 5-HT2A receptor agonist binding in vivo. Our data suggest that Cimbi-36 and altanserin both bind to 5-HT2A receptors, but in regions with high 5-HT2C receptor density, choroid plexus and hippocampus, the [(11)C]Cimbi-36 binding likely represents binding to both 5-HT2A and 5-HT2C receptors.
INTRODUCTION: [(11)C]Cimbi-36 is a recently developed serotonin 2A (5-HT2A) receptor agonist positron emission tomography (PET) radioligand that has been successfully applied for human neuroimaging. Here, we investigate the test-retest variability of cerebral [(11)C]Cimbi-36 PET and compare [(11)C]Cimbi-36 and the 5-HT2A receptor antagonist [(18)F]altanserin. METHODS: Sixteen healthy volunteers (mean age 23.9 ± 6.4years, 6 males) were scanned twice with a high resolution research tomography PET scanner. All subjects were scanned after a bolus of [(11)C]Cimbi-36; eight were scanned twice to determine test-retest variability in [(11)C]Cimbi-36 binding measures, and another eight were scanned after a bolus plus constant infusion with [(18)F]altanserin. Regional differences in the brain distribution of [(11)C]Cimbi-36 and [(18)F]altanserin were assessed with a correlation of regional binding measures and with voxel-based analysis. RESULTS: Test-retest variability of [(11)C]Cimbi-36 non-displaceable binding potential (BPND) was consistently <5% in high-binding regions and lower for reference tissue models as compared to a 2-tissue compartment model. We found a highly significant correlation between regional BPNDs measured with [(11)C]Cimbi-36 and [(18)F]altanserin (mean Pearson's r: 0.95 ± 0.04) suggesting similar cortical binding of the radioligands. Relatively higher binding with [(11)C]Cimbi-36 as compared to [(18)F]altanserin was found in the choroid plexus and hippocampus in the human brain. CONCLUSIONS: Excellent test-retest reproducibility highlights the potential of [(11)C]Cimbi-36 for PET imaging of 5-HT2A receptor agonist binding in vivo. Our data suggest that Cimbi-36 and altanserin both bind to 5-HT2A receptors, but in regions with high 5-HT2C receptor density, choroid plexus and hippocampus, the [(11)C]Cimbi-36 binding likely represents binding to both 5-HT2A and 5-HT2C receptors.
Authors: Jaya Prabhakaran; Kiran Kumar Solingapuram Sai; Francesca Zanderigo; Harry Rubin-Falcone; Matthew J Jorgensen; Jay R Kaplan; Katharine I Tooke; Akiva Mintz; J John Mann; J S Dileep Kumar Journal: Bioorg Med Chem Lett Date: 2016-11-16 Impact factor: 2.823
Authors: Vincent Beliveau; Melanie Ganz; Ling Feng; Brice Ozenne; Liselotte Højgaard; Patrick M Fisher; Claus Svarer; Douglas N Greve; Gitte M Knudsen Journal: J Neurosci Date: 2017-01-04 Impact factor: 6.167
Authors: Natasha S R Bidesi; Ida Vang Andersen; Albert D Windhorst; Vladimir Shalgunov; Matthias M Herth Journal: J Neurochem Date: 2021-10-03 Impact factor: 5.546
Authors: Franz X Vollenweider; Alan Anticevic; Katrin H Preller; Joshua B Burt; Jie Lisa Ji; Charles H Schleifer; Brendan D Adkinson; Philipp Stämpfli; Erich Seifritz; Grega Repovs; John H Krystal; John D Murray Journal: Elife Date: 2018-10-25 Impact factor: 8.140
Authors: Christian B M Poulie; Anders A Jensen; Adam L Halberstadt; Jesper L Kristensen Journal: ACS Chem Neurosci Date: 2019-11-12 Impact factor: 5.780
Authors: David Erritzoe; Abhishekh H Ashok; Graham E Searle; Alessandro Colasanti; Samuel Turton; Yvonne Lewis; Mickael Huiban; Sara Moz; Jan Passchier; Azeem Saleem; John Beaver; Anne Lingford-Hughes; David J Nutt; Oliver D Howes; Roger N Gunn; Gitte M Knudsen; Eugenii A Rabiner Journal: Neuropsychopharmacology Date: 2019-11-12 Impact factor: 8.294